GleamWall
中文EN

PLX Protalix BioTherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1006281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.0%
TTM net income YoY281.0%
TTM EPS YoY200.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR24.6%

Margins

Gross margin71.2%
Operating margin29.8%
Net margin24.3%
FCF margin17.8%
EBITDA margin31.7%

Returns

ROE30.8%
ROA20.5%
ROIC (approx.)41.0%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets31.9%
Debt / equity0.00x
Current ratio3.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio3.0%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$52.74M$53.40M$65.49M$47.64M$38.35M
Cost of revenue$26.99M$24.32M$22.98M$19.59M$16.35M
Gross profit$25.75M$29.08M$42.51M$28.05M$22.00M
R&D expense$19.57M$12.97M$17.09M$29.35M$29.73M
SG&A expense$11.68M$12.19M$14.96M$11.71M$12.73M
Operating income-$5.50M$3.92M$10.46M-$13.01M-$20.46M
Pretax income-$5.61M$4.15M$8.57M-$14.40M-$27.58M
Income tax$996,000$1.22M$254,000$530,000—
Net income-$6.60M$2.93M$8.31M-$14.93M-$27.58M
EBITDA-$4.04M$5.22M$11.65M-$11.93M-$19.34M
EPS (basic)-0.080.040.12-0.31-0.62
EPS (diluted)-0.080.040.09-0.31-0.62
Weighted avg. shares (diluted)78.55M81.06M82.42M48.47M44.14M
Balance sheet
Cash & equivalents$14.68M$19.76M$23.63M$17.11M$38.98M
Receivables$8.84M$2.91M$5.27M$4.59M$3.44M
Inventory$25.73M$21.24M$19.05M$16.80M$17.95M
Current assets$66.67M$60.08M$69.93M$44.88M$61.67M
PP&E, net$4.88M$4.59M$4.97M$4.55M$4.96M
Total assets$82.35M$73.42M$84.43M$55.79M$73.67M
Current liabilities$26.52M$25.62M$45.53M$32.43M$33.18M
Total liabilities$34.12M$30.21M$50.87M$66.43M$79.70M
Shareholders' equity$48.23M$43.21M$33.57M-$10.64M-$6.04M
Shares outstanding80.43M75.85M72.95M53.79M45.56M
Cash flow statement
Operating cash flow-$11.99M$8.67M-$1.32M-$25.00M-$10.29M
Capital expenditure$1.64M$1.28M$1.15M$628,000$1.46M
Free cash flow-$13.63M$7.39M-$2.47M-$25.63M-$11.74M
Investing cash flow-$2.37M$4.22M-$16.71M-$5.04M$18.92M
Financing cash flow$9.33M-$16.79M$24.67M$8.24M$12.08M
Depreciation & amortization$1.47M$1.30M$1.19M$1.09M$1.12M
Stock-based compensation$2.30M$3.25M$3.45M$2.08M$2.38M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.